JP5599610B2 - Ｈｓｐ９０の阻害による神経変性疾患の処置 - Google Patents

Ｈｓｐ９０の阻害による神経変性疾患の処置 Download PDF

Info

Publication number
JP5599610B2
JP5599610B2 JP2009518602A JP2009518602A JP5599610B2 JP 5599610 B2 JP5599610 B2 JP 5599610B2 JP 2009518602 A JP2009518602 A JP 2009518602A JP 2009518602 A JP2009518602 A JP 2009518602A JP 5599610 B2 JP5599610 B2 JP 5599610B2
Authority
JP
Japan
Prior art keywords
tau
hsp90
brain
protein
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009518602A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009542716A (ja
JP2009542716A5 (OSRAM
Inventor
チオシス、ガブリエラ
グリーンガード、ポール
ドウ、フェイ
ルオ、ウェンジー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of JP2009542716A publication Critical patent/JP2009542716A/ja
Publication of JP2009542716A5 publication Critical patent/JP2009542716A5/ja
Application granted granted Critical
Publication of JP5599610B2 publication Critical patent/JP5599610B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009518602A 2006-06-30 2007-07-02 Ｈｓｐ９０の阻害による神経変性疾患の処置 Expired - Fee Related JP5599610B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80642706P 2006-06-30 2006-06-30
US60/806,427 2006-06-30
PCT/US2007/072671 WO2008005937A2 (en) 2006-06-30 2007-07-02 Treatment of neurodegenerative diseases through inhibiton of hsp90

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013058040A Division JP5824698B2 (ja) 2006-06-30 2013-03-21 Ｈｓｐ９０の阻害による神経変性疾患の処置

Publications (3)

Publication Number Publication Date
JP2009542716A JP2009542716A (ja) 2009-12-03
JP2009542716A5 JP2009542716A5 (OSRAM) 2010-09-02
JP5599610B2 true JP5599610B2 (ja) 2014-10-01

Family

ID=38895418

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2009518602A Expired - Fee Related JP5599610B2 (ja) 2006-06-30 2007-07-02 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2013058040A Expired - Fee Related JP5824698B2 (ja) 2006-06-30 2013-03-21 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2015174609A Pending JP2016028063A (ja) 2006-06-30 2015-09-04 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2017110721A Expired - Fee Related JP6427227B2 (ja) 2006-06-30 2017-06-05 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2018202024A Expired - Fee Related JP6585266B2 (ja) 2006-06-30 2018-10-26 Ｈｓｐ９０の阻害による神経変性疾患の処置

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2013058040A Expired - Fee Related JP5824698B2 (ja) 2006-06-30 2013-03-21 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2015174609A Pending JP2016028063A (ja) 2006-06-30 2015-09-04 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2017110721A Expired - Fee Related JP6427227B2 (ja) 2006-06-30 2017-06-05 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2018202024A Expired - Fee Related JP6585266B2 (ja) 2006-06-30 2018-10-26 Ｈｓｐ９０の阻害による神経変性疾患の処置

Country Status (8)

Country Link
US (5) US10336757B2 (OSRAM)
EP (2) EP3305297A1 (OSRAM)
JP (5) JP5599610B2 (OSRAM)
AU (1) AU2007269144B2 (OSRAM)
CA (1) CA2656202C (OSRAM)
DK (1) DK2034839T3 (OSRAM)
ES (1) ES2645095T3 (OSRAM)
WO (1) WO2008005937A2 (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834181B2 (en) * 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7595401B2 (en) * 2006-05-12 2009-09-29 Myriad Pharmaceuticals, Inc. Therapeutic compounds and their use in cancer
US10336757B2 (en) * 2006-06-30 2019-07-02 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of HSP90
EA019103B1 (ru) 2007-03-20 2014-01-30 Кьюрис, Инк. Конденсированный аминопиридин в качестве ингибиторов hsp90
JP2011503206A (ja) * 2007-11-14 2011-01-27 ミレクシス， インコーポレイテッド 疾患および障害の治療における治療化合物およびその使用方法
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
PL2659904T3 (pl) 2008-06-26 2016-01-29 Orphazyme Aps Zastosowanie Hsp70 jako regulatora aktywności enzymatycznej
JP2012529535A (ja) 2009-06-12 2012-11-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼモジュレーターとして有用なニコチンアミド化合物
AU2013204109B2 (en) * 2009-10-07 2016-05-05 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
AU2010303343B2 (en) 2009-10-07 2015-11-19 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as HSP90 inhibitors
DK2646044T3 (da) 2010-11-30 2019-11-25 Orphazyme As Metoder til at øge den intracellulære aktivitet af Hsp70
KR102010222B1 (ko) 2011-04-05 2019-08-13 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 억제제
CA2832099C (en) 2011-04-05 2019-07-09 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
CN104081203B (zh) 2011-07-08 2018-07-31 索隆-基特林癌症研究协会 标记的hsp90抑制剂的用途
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
WO2014025395A1 (en) * 2012-08-06 2014-02-13 Duke University Compounds and methods for targeting hsp90
SG11201505631PA (en) 2013-01-23 2015-08-28 Astrazeneca Ab Chemical compounds
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
CA2921571C (en) * 2013-08-16 2022-04-05 Memorial Sloan-Kettering Cancer Center Selective grp94 inhibitors and uses thereof
AU2014318826B2 (en) 2013-09-10 2019-10-10 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
EP3086792B1 (en) 2013-12-23 2022-10-12 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
WO2015116774A1 (en) 2014-01-29 2015-08-06 Synta Pharmaceuticals Corp. Targeted therapeutics
AU2015224576A1 (en) 2014-03-03 2016-09-22 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
KR20250069686A (ko) 2014-09-15 2025-05-19 제브라 덴마크 에이/에스 아리모클로몰 제제
EA201790444A1 (ru) * 2014-09-17 2017-08-31 Мемориал Слоун Кеттеринг Кэнсэ Сентр Hsp90-направленная визуализация и терапия воспаления и инфекции
BR112018006572A2 (pt) 2015-10-05 2018-10-09 Memorial Sloan Kettering Cancer Center terapia de combinação racional para o tratamento de câncer
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
WO2017184956A1 (en) 2016-04-22 2017-10-26 Duke University Compounds and methods for targeting hsp90
LT3448382T (lt) 2016-04-29 2021-04-12 Orphazyme A/S Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti
TN2019000290A1 (en) 2017-03-20 2021-05-07 Forma Therapeutics Inc Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
US20200069592A1 (en) * 2017-04-24 2020-03-05 Samus Therapeutics, Inc. Hsp90 inhibitor oral formulations and related methods
KR20200016875A (ko) 2017-06-20 2020-02-17 마드리갈 파마슈티칼스 인코포레이티드 표적화 치료제
AU2018289349A1 (en) 2017-06-20 2020-01-02 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics
WO2018237211A2 (en) * 2017-06-23 2018-12-27 Samus Therapeutics, Inc. Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof
WO2019226213A2 (en) 2018-03-08 2019-11-28 Incyte Corporation AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼｒの活性化
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
BR112022004715A2 (pt) 2019-09-19 2022-06-14 Forma Therapeutics Inc Composições de ativação de piruvato quinase r (pkr)
US20230416224A1 (en) 2020-11-19 2023-12-28 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2287387C (en) 1997-05-14 2010-02-16 Sloan-Kettering Institute For Cancer Research Methods and compositions for destruction of selected proteins
EP1169319A4 (en) 1999-04-09 2005-02-09 Sloan Kettering Institutefor C METHODS AND COMPOSITIONS FOR DEGRADING AND / OR INHIBITING TYROSINE KINASES BELONGING TO THE HER FAMILY
CA2426952C (en) 2000-11-02 2012-06-26 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
WO2002094259A1 (en) * 2001-05-03 2002-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
WO2003037860A2 (en) * 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
US7553979B2 (en) * 2001-11-09 2009-06-30 Conforma Therapeutics Corporation HSP90-inhibiting zearalanol compounds and methods of producing and using same
WO2003072575A1 (en) 2002-02-28 2003-09-04 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents
WO2004094647A2 (en) 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
WO2005012482A2 (en) 2003-06-30 2005-02-10 Sloan-Kettering Institute For Cancer Research Assay for identification of bioactive compounds that interact with heat shock protein 90
US7138401B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation 2-aminopurine analogs having HSP90-inhibiting activity
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) * 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
CN101180275B (zh) * 2005-02-25 2014-09-10 瑟瑞耐克斯有限公司 四氢吲哚酮和四氢吲唑酮衍生物
WO2006130469A1 (en) 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules
US20110263693A1 (en) 2006-03-31 2011-10-27 Dana-Farber Cancer Institute, Inc. Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
US7595401B2 (en) * 2006-05-12 2009-09-29 Myriad Pharmaceuticals, Inc. Therapeutic compounds and their use in cancer
US10336757B2 (en) 2006-06-30 2019-07-02 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of HSP90
US20100204093A1 (en) 2006-07-27 2010-08-12 University Of Florida Research Foundation, Inc Use of heat shock activators for tissue regeneration
EP2061772A4 (en) * 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
GB0622084D0 (en) 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
WO2008070472A2 (en) 2006-11-27 2008-06-12 University Of Maryland, Baltimore Use of plasma hsp90 related to malignancy
US20080234297A1 (en) * 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
EA019103B1 (ru) * 2007-03-20 2014-01-30 Кьюрис, Инк. Конденсированный аминопиридин в качестве ингибиторов hsp90
US20100240656A1 (en) 2007-07-12 2010-09-23 Oryzon Genomics, S.A. Compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
JP2011503206A (ja) 2007-11-14 2011-01-27 ミレクシス， インコーポレイテッド 疾患および障害の治療における治療化合物およびその使用方法
AU2010303343B2 (en) 2009-10-07 2015-11-19 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as HSP90 inhibitors
KR102010222B1 (ko) 2011-04-05 2019-08-13 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 억제제
CA2832099C (en) 2011-04-05 2019-07-09 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
CA2921571C (en) 2013-08-16 2022-04-05 Memorial Sloan-Kettering Cancer Center Selective grp94 inhibitors and uses thereof

Also Published As

Publication number Publication date
JP6585266B2 (ja) 2019-10-02
JP5824698B2 (ja) 2015-11-25
JP2009542716A (ja) 2009-12-03
US12473288B2 (en) 2025-11-18
JP2016028063A (ja) 2016-02-25
AU2007269144A1 (en) 2008-01-10
JP2019038829A (ja) 2019-03-14
EP2034839A2 (en) 2009-03-18
US20090298857A1 (en) 2009-12-03
JP2017214379A (ja) 2017-12-07
ES2645095T3 (es) 2017-12-04
DK2034839T3 (en) 2017-12-04
US20140378452A1 (en) 2014-12-25
US20230060990A1 (en) 2023-03-02
CA2656202C (en) 2018-01-16
EP3305297A1 (en) 2018-04-11
JP2013177389A (ja) 2013-09-09
EP2034839A4 (en) 2012-08-29
US10336757B2 (en) 2019-07-02
AU2007269144B2 (en) 2013-05-16
WO2008005937A2 (en) 2008-01-10
WO2008005937A3 (en) 2008-12-11
US20240158397A1 (en) 2024-05-16
JP6427227B2 (ja) 2018-11-21
US20190389864A1 (en) 2019-12-26
CA2656202A1 (en) 2008-01-10
EP2034839B1 (en) 2017-08-23

Similar Documents

Publication Publication Date Title
JP6585266B2 (ja) Ｈｓｐ９０の阻害による神経変性疾患の処置
Nguyen et al. Cycling at the interface between neurodevelopment and neurodegeneration
JP2009535321A (ja) Ｇｓｋ−３阻害剤としてのｎ−（２−チアゾリル）アミド誘導体
JP2011504474A (ja) アルツハイマー氏病を治療するためのＭｎｋインヒビターの使用
CN107820518B (zh) 用于选择磷酸酶选择性抑制剂和非选择性磷酸酶抑制剂的方法
Hartz et al. Discovery of 2-(anilino) pyrimidine-4-carboxamides as highly potent, selective, and orally active glycogen synthase kinase-3 (GSK-3) inhibitors
Kesavapany et al. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5
CN107969126A (zh) Jnk信号转导通路的细胞穿透肽抑制剂用于治疗轻度认知损害的新用途
EP3177310A1 (en) Compositions and methods for identifying and treating conditions involving hsf1 activity
AU2017200078C1 (en) Treatment of neurodegenerative diseases through inhibition of Hsp90
HK1253803A1 (en) Treatment of neurodegenerative diseases through inhibition of hsp90
WO2013149976A1 (en) Indole-pyrimidine derivatives and their therapeutic uses
JP2019501972A (ja) Ｔｄｐ−４３タンパク質症の治療のためのタクロリムス
EP2970118B1 (en) Compounds for the treatment of neurological disorders
EP2662081A1 (en) Therapeutic use of indole-dihydro-imidazole derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130118

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130321

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140718

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140813

R150 Certificate of patent or registration of utility model

Ref document number: 5599610

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees